Clinical trials: Skin Toxicity
Breast Cancer, Lymphoma
Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)
The purpose of this research study is to see if Atorvastatin (Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in individuals receiving adjuvant anthracycline-based chemotherapy for breast cancer of…
- Trial name
- NCT01988571
- Testing
- Atorvastatin
- Where
- 51 sites in United States
- Volunteers
- 279 people
- Sponsor
- Wake Forest University Health Sciences
Toxic Epidermal Necrolysis
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
The primary objectives of this study are to investigate the efficacy and safety of topical steroid ointment (clobetasol 0.05%) for the treatment of the cutaneous manifestations of toxic epidermal necrolysis (TEN).
- Trial name
- TEN (NCT02319616)
- Testing
- Clobetasol 0.05% ointment
- Where
- United States
- Sponsor
- University of California, Davis
Skin Toxicity
Potency of Topical Corticosteroids in Combination Preparations
Several combination topical drugs are available on the market. The potency of corticosteroids depends on a particular molecular structure and the skin penetration properties.
- Trial name
- NCT03606954
- Testing
- Combination topical corticosteroid
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ben-Gurion University of the Negev
Breast Cancer
Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients
Early identification of patients at risk for cardiotoxicity represent a primary goal for cardiologist and oncologist From all adjuvant trials echocardiography is ideal for evaluating Left Ventricular function though its operator…
- Trial name
- NCT02062983
- Testing
- Herceptin
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- National Guard Health Affairs
Breast Cancer, Adverse Effect of Radiation Therapy
Evaluation of Two Boost Radiation Schedules in Post Lumpectomy Early Stage Carcinoma Breast
In a general radiation oncology practice, breast cancer typically comprises approximately 25% of the total patient caseload.1 Surgery is the primary modality of treatment.
- Trial name
- NCT02142907
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Breast Cancer, Lymphoma, Large B-Cell, Diffuse
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines
As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised.
- Conditions
- Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity, Left Ventricular Dysfunction
- Trial name
- CONTROL (NCT05728632)
- Testing
- Nebivolol
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Giulio Stefanini
Rheumatoid Arthritis
Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
To stimulate collaborative efforts of federal funding agencies, voluntary health agencies, professional organizations and industry partners to enable creation of a large, sustainable database and repository to better understand…
- Trial name
- TETRAD (NCT01070121)
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Alabama at Birmingham
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Colorectal Cancer, Skin Toxicities
Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment
Up to 60% of patients with metastatic colorectal cancer can be treated with one of monoclonal antibodies targeted against epidermal growth factor receptor (EGFR).
- Trial name
- STLDD-1 (NCT01380262)
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Anesthesia, Local, Photodamaged Skin
Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face
The purpose of this study is to determine the efficacy of lidocaine 2.5%/prilocaine 2.5% cream versus lidocaine 23%/tetracaine 7% ointment for topical anesthesia prior to a nonablative laser procedure.
- Conditions
- Anesthesia, Local, Photodamaged Skin, Topical and Infiltration Anesthetic Toxicity
- Trial name
- NCT04523961
- Testing
- 2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion, 7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Radiation Toxicity, Recurrent Breast Cancer
Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy
This phase II trial is studying how well alkaline water works in reducing skin toxicity in women with breast cancer undergoing radiation therapy.
- Conditions
- Radiation Toxicity, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01487954
- Testing
- alkaline water, distilled water, external beam radiation therapy (EBRT)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
This phase II trial studies the side effects and how well radiation therapy works in treating patients with stage 0-II breast cancer.
- Conditions
- Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7
- Trial name
- NCT01245712
- Testing
- Accelerated Partial Breast Irradiation, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast Cancer
The purpose of this study is to evaluate clinical outcomes and adverse events of salvage treatment for locoregional recurrence of breast cancer.
- Trial name
- SALT-LRR (NCT05933733)
- Testing
- Salvage treatment (surgery and/or radiation therapy)
- Where
- South Korea
- Volunteers
- 190 people
- Sponsor
- Samsung Medical Center
Cancer, Breast, LV Dysfunction
Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging
The main objective of this study is to compare the proportions of late enhancement in patients with Left ventricular (LV) dysfunction as Herceptin ® and in a control group consisting of patients who did not have LV dysfunction…
- Trial name
- MRTOX (NCT01436604)
- Testing
- Cardiac MRI
- Where
- 4 sites in France
- Volunteers
- 19 people
- Sponsor
- Centre Francois Baclesse
Malignant Breast Neoplasm
Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy
The reduction in the number of fractions in radiotherapy is especially attractive in several senses, and even more so considering breast cancer, which has a high incidence and generally favorable prognosis.
- Trial name
- HYPHEN (NCT05665920)
- Testing
- Ultra-hypofractionated whole breast radiotherapy, Standard Radiation
- Where
- Brazil
- Volunteers
- 36 people
- Sponsor
- Instituto Brasileiro de Controle do Cancer
Breast Cancer
A Study to Develop Molecular Integrated Predictive Models of Breast Radio-toxicity (Precise-RTox)
Breast radiation treatment is burdened by acute and chronic toxicities, in most cases mild. However, considering the excellent life expectancy of patients with breast cancer, maintaining a low toxicity profile is of primary…
- Trial name
- (Precise-RTox) (NCT06114589)
- Where
- Italy
- Volunteers
- 420 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Hematological Toxicity, Targeted Therapy
Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer
This multicenter, real-world, observational study will retrospectively and prospectively collect real-world data related to the investigational drugs.
- Conditions
- Hematological Toxicity, Targeted Therapy, Breast Cancer
- Trial name
- NCT06503380
- Testing
- No intervenrion.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Fudan University
Metastatic Colon Cancer
Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response
Colon cancer is one of the most common cancers in France with more than 36,000 new cases per year. Despite significant advances in therapeutic care, the prognosis of colon cancers with metastases remains bad.
- Trial name
- NCT01292356
- Testing
- cetuximab
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Poitiers University Hospital
Breast Cancer, Familial Male, Radiotherapy; Complications
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
Radiation therapy is a crucial part in the comprehensive treatment of breast cancer. In recent years, emerging systemic treatment regimens such as HER 2 inhibitors, CDK 4/6 inhibitors, PARP inhibitors, capecitabine and PD1…
- Conditions
- Breast Cancer, Familial Male, Radiotherapy; Complications, Chemotherapeutic Toxicity, Immune Checkpoint Inhibitor
- Trial name
- RADIOCOM (NCT06197581)
- Testing
- Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Investigation of Genetic Determinants of Capecitabine Toxicity
The purpose of this study is to identify possible genetic polymorphisms that contribute to specific toxicities associated with capecitabine (hand-foot syndrome, diarrhea, and neutropenia).
- Trial name
- NCT00977119
- Testing
- Side-effect questionnaires, research blood samples
- Where
- 13 sites in United States
- Volunteers
- 240 people
- Sponsor
- University of Chicago